Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn`s disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Website: lianbio.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 73.7% (LTM)

Entry Point: Share price is 0.0% higher than minimum and 99.9% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: LIAN
Share price, USD:  (0.0%)0.319
year average price 0.3190  


year start price 0.3190 2025-01-08

max close price 0.3190 2025-01-08

min close price 0.3190 2025-01-08

current price 0.3190 2026-01-07
Common stocks: 110 628 995

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 35
Net Debt ($m): -135
EV (Enterprise Value): -100
Price to Book: 0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-15InvestorPlace

Why Is LianBio (LIAN) Stock Moving Today?

2023-11-08Zacks Investment Research

All You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong Buy

2023-10-27The Motley Fool

Why LianBio Stock Is Shooting Through the Roof This Week

2023-10-24InvestorPlace

Why Is LianBio (LIAN) Stock Up 130% Today?

2023-10-24The Motley Fool

Why LianBio Stock Is Skyrocketing Today

2023-06-01GlobeNewsWire

LianBio to Participate in Upcoming Investor Conferences
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol LIAN LIAN LIAN LIAN LIAN LIAN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-13 2023-08-14 2023-05-11 2023-03-28 2022-11-10 2022-08-11
acceptedDate 2023-11-13 16:28:38 2023-08-14 16:21:44 2023-05-11 16:33:14 2023-03-28 17:23:30 2022-11-10 16:33:32 2022-08-11 16:44:58
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 0
costOfRevenue 300 018 296 781 0 0 0 0
grossProfit -300 018 -296 781 0 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 9M 9M 11M 11M 8M 29M
generalAndAdministrativeExpenses 17M 16M 15M 19M 16M 15M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 17M 16M 15M 19M 16M 15M
otherExpenses 0 869 000 -44 000 9M 0 203 000
operatingExpenses 26M 25M 26M 29M 25M 43M
costAndExpenses 26M 25M 26M 29M 25M 43M
interestIncome 3M 3M 2M 3M 1M 553 000
interestExpense 0 0 -2M -12M 1M 0
depreciationAndAmortization 325 000 334 000 324 000 317 000 280 000 138 000
ebitda -26M -25M -26M -29M -24M -42M
ebitdaratio 0 0 0 0 0 0
operatingIncome -26M -25M -26M -29M -25M -43M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet 3M 4M 2M 11M 3M 203 000
incomeBeforeTax -23M -21M -24M -19M -22M -42M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 586 000 200 000 438 000 -350 000 6000 5000
netIncome -24M -22M -24M -18M -22M -42M
netIncomeRatio 0 0 0 0 0 0
eps -0.22 -0.2 -0.22 -0.17 -0.2 -0.39
epsdiluted -0.22 -0.2 -0.22 -0.17 -0.2 -0.39
weightedAverageShsOut 107M 107M 107M 108M 108M 108M
weightedAverageShsOutDil 107M 107M 107M 108M 108M 108M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol LIAN LIAN LIAN LIAN LIAN LIAN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-13 2023-08-14 2023-05-11 2023-03-28 2022-11-10 2022-08-11
acceptedDate 2023-11-13 16:28:38 2023-08-14 16:21:44 2023-05-11 16:33:14 2023-03-28 17:23:30 2022-11-10 16:33:32 2022-08-11 16:44:58
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 103M 104M 102M 79M 79M 134M
shortTermInvestments 149M 163M 184M 223M 233M 195M
cashAndShortTermInvestments 252M 267M 287M 302M 312M 329M
netReceivables 2M 1M 4M 2M 9M 9M
inventory 0 0 -4M 0 0 0
otherCurrentAssets 4M 4M 10M 9M 3M 6M
totalCurrentAssets 258M 273M 296M 313M 324M 344M
propertyPlantEquipmentNet 5M 6M 6M 7M 7M 8M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 0 68 997 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 89 013 20 003 93 000 93 000 20M 20M
totalNonCurrentAssets 5M 6M 7M 7M 28M 28M
otherAssets 0 0 0 0 0 0
totalAssets 263M 279M 303M 320M 352M 372M
accountPayables 6M 2M 5M 1M 2M 1M
shortTermDebt 2M 4M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 17M 0 0 0 0
otherCurrentLiabilities 18M 16M 19M 20M 18M 19M
totalCurrentLiabilities 26M 22M 26M 24M 22M 22M
longTermDebt 950 000 1M 2M 2M 3M 4M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 213 000 210 000 217 000 210 000 19M 20M
totalNonCurrentLiabilities 1M 2M 2M 3M 23M 24M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 3M 3M 4M 4M 5M 5M
totalLiabilities 27M 23M 28M 26M 45M 46M
preferredStock 0 0 0 0 0 0
commonStock 1999.995 2000 2000 2000 2000 2000
retainedEarnings -540M -516M -495M -471M -452M -430M
accumulatedOtherComprehensiveIncomeLoss -3M -3M -2M -2M -4M -1M
othertotalStockholdersEquity 746M 741M 737M 732M 729M 724M
totalStockholdersEquity 202M 222M 241M 260M 273M 292M
totalEquity 236M 256M 274M 260M 273M 292M
totalLiabilitiesAndStockholdersEquity 263M 279M 303M 320M 352M 372M
minorityInterest 34M 34M 34M 34M 0 0
totalLiabilitiesAndTotalEquity 263M 279M 303M 320M 352M 372M
totalInvestments 149M 163M 184M 223M 233M 0
totalDebt 3M 3M 4M 4M 5M 5M
netDebt -101M -101M -98M -75M -74M -129M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol LIAN LIAN LIAN LIAN LIAN LIAN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-13 2023-08-14 2023-05-11 2023-03-28 2022-11-10 2022-08-11
acceptedDate 2023-11-13 16:28:38 2023-08-14 16:21:44 2023-05-11 16:33:14 2023-03-28 17:23:30 2022-11-10 16:33:32 2022-08-11 16:44:58
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -24M -22M -24M -18M -22M -42M
depreciationAndAmortization 325 000 334 000 324 000 317 000 280 000 138 000
deferredIncomeTax 0 0 0 0 0 0
stockBasedCompensation 5M 4M 4M 5M 5M 5M
changeInWorkingCapital 4M -149 000 3M -2M 3M -2M
accountsReceivables 115 000 -15 054 0 0 0 0
inventory 0 15 054 0 0 0 0
accountsPayables 4M -4M 4M -614 000 866 000 -6M
otherWorkingCapital -325 000 3M -918 000 -2M 2M 0
otherNonCashItems -951 489 -2M -1M -16M -2M 0
netCashProvidedByOperatingActivities -16M -19M -18M -31M -16M -39M
investmentsInPropertyPlantAndEquipment -160 000 -50 000 -19 000 -235 000 -937 000 -329 000
acquisitionsNet 0 -22 022 0 0 0 0
purchasesOfInvestments -40M -42M -46M -43M -134M -33M
salesMaturitiesOfInvestments 56M 64M 86M 54M 97M 67M
otherInvestingActivites 0 22 022 0 0 0 0
netCashUsedForInvestingActivites 16M 22M 41M 11M -39M 34M
debtRepayment 0 0 0 0 0 0
commonStockIssued 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 0 2M 0 2M
netCashUsedProvidedByFinancingActivities 0 0 0 2M 0 2M
effectOfForexChangesOnCash -266 000 -933 000 201 000 79 000 -1M -1M
netChangeInCash -602 000 2M 23M -20M -55M -5M
cashAtEndOfPeriod 104M 104M 102M 79M 99M 154M
cashAtBeginningOfPeriod 104M 102M 79M 99M 154M 160M
operatingCashFlow -16M -19M -18M -31M -16M -39M
capitalExpenditure -160 000 -50 000 -19 000 -235 000 -937 000 -329 000
freeCashFlow -16M -19M -18M -31M -17M -40M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2023-11-13 16:28 ET
LianBio reported for 2023 q3
SEC form 8
2023-11-13 00:00 ET
LianBio reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
LianBio reported for 2023 q3
SEC form 10
2023-08-14 16:21 ET
LianBio reported for 2023 q2
SEC form 6
2023-08-14 16:11 ET
LianBio reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
LianBio reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
LianBio reported for 2023 q2
SEC form 6
2023-06-23 16:17 ET
LianBio published news for 2023 q1
SEC form 10
2023-05-11 16:33 ET
LianBio reported for 2023 q1
SEC form 6
2023-05-11 16:23 ET
LianBio reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
LianBio reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
LianBio reported for 2023 q1
SEC form 6
2023-05-01 07:28 ET
LianBio published news for 2023 q1
SEC form 6
2023-04-26 08:07 ET
LianBio published news for 2023 q1
SEC form 6
2023-04-21 16:13 ET
LianBio published news for 2023 q1
SEC form 6
2023-04-19 16:17 ET
LianBio published news for 2023 q1
SEC form 10
2023-03-28 17:23 ET
LianBio reported for 2022 q4
SEC form 10
2023-03-28 00:00 ET
LianBio reported for 2022 q4
SEC form 6
2023-03-27 08:40 ET
LianBio reported for 2022 q4
SEC form 8
2023-03-27 00:00 ET
LianBio reported for 2022 q4
SEC form 6
2023-03-17 16:05 ET
LianBio published news for 2022 q4
SEC form 6
2022-12-19 07:04 ET
LianBio published news for 2022 q3
SEC form 6
2022-12-13 17:03 ET
LianBio published news for 2022 q3
SEC form 10
2022-11-10 16:33 ET
LianBio reported for 2022 q3
SEC form 6
2022-11-10 16:16 ET
LianBio reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
LianBio reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
LianBio reported for 2022 q3
SEC form 6
2022-10-12 16:20 ET
LianBio published news for 2022 q3
SEC form 10
2022-08-11 16:44 ET
LianBio reported for 2022 q2
SEC form 6
2022-08-11 16:30 ET
LianBio reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
LianBio reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
LianBio reported for 2022 q2
SEC form 6
2022-06-10 16:14 ET
LianBio published news for 2022 q1
SEC form 10
2022-05-12 16:39 ET
LianBio reported for 2022 q1
SEC form 6
2022-05-12 09:15 ET
LianBio published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
LianBio reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
LianBio reported for 2022 q1
SEC form 6
2022-04-27 08:17 ET
LianBio published news for 2022 q1
SEC form 6
2022-04-08 16:22 ET
LianBio published news for 2022 q1
SEC form 6
2022-04-08 16:10 ET
LianBio published news for 2022 q1
SEC form 10
2022-03-31 08:55 ET
LianBio published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
LianBio published news for 2021 q4
SEC form 6
2022-03-30 16:55 ET
LianBio published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
LianBio published news for 2021 q4
SEC form 6
2022-03-02 16:42 ET
LianBio published news for 2021 q4
SEC form 6
2022-01-10 16:06 ET
LianBio published news for 2021 q4
SEC form 10
2021-12-09 17:24 ET
LianBio published news for 2021 q3
SEC form 6
2021-12-09 16:59 ET
LianBio published news for 2021 q3
SEC form 8
2021-12-09 00:00 ET
LianBio published news for 2021 q3
SEC form 6
2021-11-10 16:30 ET
LianBio published news for 2021 q3
SEC form 6
2021-11-09 16:05 ET
LianBio published news for 2021 q3
SEC form 6
2021-11-03 16:01 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:20 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:18 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:16 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:16 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:15 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:12 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:11 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:10 ET
LianBio published news for 2021 q3
SEC form 6
2021-10-29 18:08 ET
LianBio published news for 2021 q3